(PBIO) Pressure BioSciences Inc. 
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.
COMPANY NEWS
Pressure BioSciences, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update (Nov 21, 2016)
Pressure BioSciences (PBIO) Achieves Record Revenue on Road to Profitability -- SECFilings.com (Nov 16, 2016)
Pressure BioSciences, Inc. Reports Third Quarter 2016 Financial Results and Provides Business Update (Nov 21, 2016)
Pressure BioSciences Announces Initial Close of $610,000 in $2.5 Million Private Placement
(Nov 14, 2016)
Pressure BioSciences (PBIO) Secures Funding Allowing for Accelerated Corporate Development -- SECFilings.com
(Nov 04, 2016)
Pressure BioSciences, Inc. Closes $2,000,000 Line-of-Credit
(Nov 03, 2016)
Pressure BioSciences' PCT Platform Featured at Official Launch of Major Cancer Research Center Recently Chosen as a Collaborator in the US "Cancer Moonshot" Initiative
October 26, 2016
Pressure BioSciences, Inc. to Present at the Fall SeeThruEquity Microcap Investment Conference in New York City
Oct. 17, 2016
SeeThruEquity Issues Update on Pressure BioSciences (OTCQB: PBIO)
October 14, 2016
Cancer Moonshot Should Benefit Pharma Companies, Investors
Sept, 6, 2016
Pressure BioSciences, Inc. Reports Second Quarter 2016 Financial Results and Provides Business Update
Aug. 16, 2016
StockWatchIndex Research Report
July 21, 2016
Pressure BioSciences Unveils Barocycler 2320EXT at Major Scientific Meeting; Next Generation PCT-based Instrument Expected to be Centerpiece of the Recently Announced Co-Marketing Agreement with Global Life Sciences Analytical Technologies Leader SCIEX
July 13, 2016
DISCLAIMER
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their owndue diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information here.